Core Viewpoint - Innovation Medical (002173) experienced a significant stock price increase, with a closing price of 36.99 yuan on January 12, 2026, reflecting a 6.78% rise from the previous trading day, and a total market capitalization of 16.323 billion yuan [1] Group 1: Stock Performance - The stock opened at 35.4 yuan, reached a high of 38.1 yuan, and a low of 34.0 yuan on January 12, 2026 [1] - The trading volume for the day was 70.25 billion yuan, with a turnover rate of 46.32% [1] Group 2: Company Announcement - The company announced that its stock price had deviated significantly, with a cumulative increase of over 20% over three consecutive trading days (January 8, 9, and 12, 2026), indicating abnormal trading fluctuations [1] - After investigation, the company confirmed that there were no corrections or supplements needed for previously disclosed information, and no significant undisclosed information affecting stock prices was found [1] - The company stated that its production and operational conditions remain normal, with no significant changes in the internal and external operating environment [1] Group 3: Shareholder Activity - During the period of abnormal stock price fluctuations, the controlling shareholder and actual controller did not buy or sell company shares [1] - The board of directors confirmed that there are currently no undisclosed matters that should be disclosed [1] Group 4: Subsidiary Operations - The company's subsidiary, Boling Brain-Machine, is engaged in brain-machine interface business, with some products already on the market; however, it is experiencing operational losses [1]

Core Viewpoint - The stock of Innovation Medical (002173.SZ) experienced a significant price fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days in January 2026, indicating abnormal trading activity [1] Group 1: Company Overview - Innovation Medical's subsidiary, Bole Brain Machine (Hangzhou) Technology Co., Ltd., was established in early 2021 and was included in the consolidated financial statements in August 2025 [1] - The primary products of Bole Brain Machine are designed for rehabilitation training of patients with cerebrovascular diseases, particularly focusing on stroke and paralysis [1] Group 2: Product and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Bole Brain Machine were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - Innovation Medical (002173.SZ) has experienced significant stock price fluctuations, with a cumulative increase of over 20% in three consecutive trading days, indicating market interest in its brain-computer interface business [1] Group 1: Company Overview - Innovation Medical's subsidiary, Boling Brain Technology (Hangzhou) Co., Ltd., was established in early 2021 and included in the consolidated financial statements in August 2025 [1] - The primary products of Boling Brain Technology are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - Boling Brain Technology reported operating losses of 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Insights - The BroncTarget lung-targeted denervation radiofrequency ablation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its core technology originality and clinical significance [1] - Targeted Lung Denervation (TLD) is a breakthrough intervention technique for moderate to severe Chronic Obstructive Pulmonary Disease (COPD), aiming to suppress airway abnormal contraction and mucus hypersecretion [1] - The BroncTarget system employs innovative designs such as circular multi-electrodes, adjustable orifices, differentiated output of radiofrequency energy, real-time monitoring of temperature and impedance, and intelligent saline infusion to ensure ablation efficiency and safety [1] Clinical Trials - Confirmatory clinical trials for the BroncTarget system are currently underway, with 28 hospitals across the country actively recruiting participants [2]

Core Viewpoint - The BroncTarget® lung denervation system has entered the special review process of the National Medical Products Administration (NMPA) in China, indicating recognition of its innovative technology and clinical value [1] Group 1: Product Overview - The BroncTarget® system is a targeted lung denervation technology aimed at treating moderate to severe Chronic Obstructive Pulmonary Disease (COPD) [1] - It utilizes a bronchoscopic approach to deliver radiofrequency energy precisely to nerve targets, aiming to suppress airway hypercontraction and mucus hypersecretion [1] - The system offers a new treatment option for patients whose symptoms remain poorly controlled despite conventional drug therapy, integrating an "intervention + medication" management strategy [1] Group 2: Technological Features - The BroncTarget® system features innovative designs such as circular multi-electrodes, adjustable orifices, differentiated radiofrequency energy output, real-time temperature and impedance monitoring, and intelligent saline infusion [1] - These features ensure the efficiency and safety of radiofrequency ablation [1] Group 3: Clinical Trials - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted simultaneously across 28 hospitals nationwide [2]

Core Viewpoint - The company, Innovation Medical (002173.SZ), has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd. [1] Group 1: Company Overview - Boling Brain Machine was established in early 2021 and is expected to be included in the company's consolidated financial statements by August 2025 [1] - The primary products are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product Development and Financial Performance - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Machine were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - Innovation Medical (002173) has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days, indicating heightened market interest in the company's brain-computer interface business [1] Group 1: Stock Performance - The company's stock price showed abnormal volatility on January 8, 9, and 12, with a cumulative price deviation exceeding 20% [1] - This fluctuation is in accordance with the trading rules of the Shenzhen Stock Exchange, categorizing it as an abnormal trading situation [1] Group 2: Business Overview - The company's subsidiary, Boling Brain Machine (Hangzhou) Technology Co., Ltd., was established in early 2021 and is focused on brain-computer interface products [1] - The primary applications of Boling Brain Machine's products are for rehabilitation training of patients with cerebrovascular diseases, particularly those suffering from stroke-related paralysis [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 3: Financial Performance - Boling Brain Machine reported operating losses of 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

Core Viewpoint - The company, Innovation Medical, has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Technology [1] Group 1: Company Overview - Boling Brain Technology was established in early 2021 and is expected to be included in the company's consolidated financial statements by August 2025 [1] - The primary products are designed for rehabilitation training of patients with cerebrovascular diseases, mainly focusing on stroke and hemiplegia [1] Group 2: Product Development and Financial Performance - The product "Cyberling Science AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberling Science AM5" has completed multi-center clinical trials but has not generated revenue in 2025 [1] - The operating losses for Boling Brain Technology were 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

Core Viewpoint - The company has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Technology (Hangzhou) Co., Ltd, which was established in early 2021 and included in the consolidated financial statements in August 2025 [1] Group 1: Company Overview - Boling Brain Technology focuses on rehabilitation training for patients with cerebrovascular diseases, primarily targeting stroke and hemiplegia patients, both in medical institutions and at home [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" product has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 2: Financial Performance - The operating losses for Boling Brain Technology were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

证券代码：002173 证券简称：创新医疗 公告编号：2026-002 创新医疗管理股份有限公司 股票交易异常波动公告 5、公司不存在违反公平信息披露规定的其他情形。 6、公司控股股东及实际控制人在本公司股票交易异常波动期间未买卖本公 司股票。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 创新医疗管理股份有限公司（以下简称"公司"）股票（证券简称：创新医 疗，股票代码：002173）于2026年1月8日、9日、12日连续三个交易日内日收盘 价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》的有关规定， 公司股票属于交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票交易异常波动情况，公司对控股股东及实际控制人、公司董事 及高级管理人员就相关问题进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3、近期公司生产经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东及实际 ...